Antibodies
9 November 2010
ABLYNX ELIGIBLE FOR MILESTONE PAYMENT AS PFIZER INITIATES PHASE I CLINICAL TRIAL WITH A SECOND ANTI-TNF-alpha NANOBODY1 November 2010
MabThera approved in Europe for first line maintenance treatment of follicular lymphoma, a common type of blood cancer29 October 2010
Compugen Licenses Novel Oncology Target to Seattle Genetics27 October 2010
Laureate Pharma Announces New Development and Manufacturing Agreement to Produce AVEO Pharmaceuticals’ Antibody Therapeutic26 October 2010
Genmab Announces Start of Ofatumumab Phase III Head to Head Study in Follicular Lymphoma26 October 2010
Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART-Based Antibody Therapeutics26 October 2010
Ablexis Cuts Deal With Pfizer Inc. (PFE), Four Other Pharmas, For Antibody Drug Discovery Tool in Deal Worth up to $50 Million21 October 2010
MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint20 October 2010
Agensys, an Affiliate of Astellas, and Seattle Genetics Announce Initiation of Phase I Clinical Trial of ASG-5ME for Prostate Cancer18 October 2010
Peregrine Reports Promising Interim Survival Data From Phase II Cotara(R) Brain Cancer Study18 October 2010
Genmab Announces Update on Zalutumumab18 October 2010
Phase II study with ocrelizumab shows significant reduction in disease activity for multiple sclerosis patients14 October 2010
Genzyme’s Alemtuzumab Shows Sustained Reduction in Relapses and Disability in Five-Year Review of MS Patients from Phase 2 TrialNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports